Martine van Glabbeke

Summary

Affiliation: EORTC Data Center
Country: Belgium

Publications

  1. ncbi request reprint Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
    M van Glabbeke
    EORTC Data Center, Av Mounier 83 11, B1200, Brussels, Belgium
    Eur J Cancer 38:543-9. 2002
  2. ncbi request reprint Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Grou
    Martine van Glabbeke
    European Organisation for Research and Treatment of Cancer Data Center, Av E Mounier, 83, Bte 8, B1200 Brussels, Belgium
    J Clin Oncol 23:5795-804. 2005
  3. ncbi request reprint Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone
    M van Glabbeke
    European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Clin Oncol 17:150-7. 1999
  4. ncbi request reprint Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study
    Elizabeth C Moser
    EORTC Data Centre, Brussels, Belgium
    Haematologica 91:1481-8. 2006
  5. ncbi request reprint Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Gr
    Martine van Glabbeke
    EORTC Data Center, Av E Mounier, 83, Bte 8, B1200, Brussels, Belgium
    Eur J Cancer 42:2277-85. 2006
  6. ncbi request reprint Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma
    Elizabeth C Moser
    European Organisation for Research and Treatment of Cancer EORTC Data Center, Brussels, Belgium
    Int J Radiat Oncol Biol Phys 66:1168-77. 2006
  7. ncbi request reprint Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005
    Jaap Verweij
    Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 43:974-8. 2007
  8. ncbi request reprint Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
    Michael Leahy
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK, and Erasmus University Medical Center, Rotterdam, Netherlands
    Eur J Cancer 43:308-15. 2007
  9. ncbi request reprint Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group
    Julie Francart
    European Organisation for Research and Treatment of Cancer
    J Clin Oncol 24:3007-12. 2006
  10. ncbi request reprint KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    Maria Debiec-Rychter
    Department of Human Genetics, University of Leuven and University Hospital Gasthuisberg, O and N Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Eur J Cancer 42:1093-103. 2006

Collaborators

Detail Information

Publications20

  1. ncbi request reprint Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
    M van Glabbeke
    EORTC Data Center, Av Mounier 83 11, B1200, Brussels, Belgium
    Eur J Cancer 38:543-9. 2002
    ....
  2. ncbi request reprint Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Grou
    Martine van Glabbeke
    European Organisation for Research and Treatment of Cancer Data Center, Av E Mounier, 83, Bte 8, B1200 Brussels, Belgium
    J Clin Oncol 23:5795-804. 2005
    ..This study is based on the European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group randomized trial comparing two doses of imatinib in advanced disease...
  3. ncbi request reprint Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone
    M van Glabbeke
    European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Clin Oncol 17:150-7. 1999
    ....
  4. ncbi request reprint Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study
    Elizabeth C Moser
    EORTC Data Centre, Brussels, Belgium
    Haematologica 91:1481-8. 2006
    ..Second cancer has been associated with non-Hodgkin's Lymphoma (NHL) treatment, but few studies have addressed this issue considering specific treatments...
  5. ncbi request reprint Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Gr
    Martine van Glabbeke
    EORTC Data Center, Av E Mounier, 83, Bte 8, B1200, Brussels, Belgium
    Eur J Cancer 42:2277-85. 2006
    ..A multivariate risk calculator that can be used in the clinic for individual patients is proposed...
  6. ncbi request reprint Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma
    Elizabeth C Moser
    European Organisation for Research and Treatment of Cancer EORTC Data Center, Brussels, Belgium
    Int J Radiat Oncol Biol Phys 66:1168-77. 2006
    ..We evaluated the impact of radiotherapy on outcome in PR patients treated in four successive European Organization for Research and Treatment of Cancer trials for aggressive NHL...
  7. ncbi request reprint Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005
    Jaap Verweij
    Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 43:974-8. 2007
    ..In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity...
  8. ncbi request reprint Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
    Michael Leahy
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK, and Erasmus University Medical Center, Rotterdam, Netherlands
    Eur J Cancer 43:308-15. 2007
    ..In the non-GIST group, this PFS is in the range of other agents considered active in STS, and may predict for more substantial first line activity. Further investigation in STS other than GIST appears warranted...
  9. ncbi request reprint Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group
    Julie Francart
    European Organisation for Research and Treatment of Cancer
    J Clin Oncol 24:3007-12. 2006
    ..To design future phase II trials, reference values for PFSRs that correspond to drugs with insufficient (P0) and sufficient (P1) clinical activity (CA) are necessary. This article provides these values in mesothelioma...
  10. ncbi request reprint KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    Maria Debiec-Rychter
    Department of Human Genetics, University of Leuven and University Hospital Gasthuisberg, O and N Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Eur J Cancer 42:1093-103. 2006
    ..Our findings suggest the need for differential treatment of patients with GISTs, with KIT exon 9 mutant patients benefiting the most from the 800 mg daily dose of the drug...
  11. ncbi request reprint Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
    John R Zalcberg
    Department of Medical Oncology, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne, VIC 8006, Australia
    Eur J Cancer 41:1751-7. 2005
    ..1% of patients were still alive and progression free one year after cross-over. We conclude that a cross-over to high-dose imatinib is feasible and safe in GIST patients who progress on low-dose therapy...
  12. ncbi request reprint Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group
    Ian Judson
    Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    Cancer Chemother Pharmacol 55:379-86. 2005
    ..6%, which contains zero. It is not yet clear whether this is a significant factor in the amelioration of imatinib toxicity that occurs with time or is related to disease control, and further work is required to confirm this observation...
  13. ncbi request reprint Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
    Jaap Verweij
    Department of Medical Oncology, Erasmus University Medical Centre, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands
    Lancet 364:1127-34. 2004
    ..Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST...
  14. ncbi request reprint Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group
    Allan T Van Oosterom
    Department of Oncology, Catholic University Hospital, Leuven, Belgium
    Eur J Cancer 38:S83-7. 2002
    ..In summary, imatinib is generally well tolerated and has significant activity during long-term treatment of patients with advanced GISTs...
  15. doi request reprint Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii35-8. 2008
  16. doi request reprint A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens
    Isabelle Ray-Coquard
    Centre Léon Bérard and UJOMM H E Herriot, Lyon, France
    Oncologist 13:467-73. 2008
    ..Based on a report showing a specific overexpression of HER-1 in SyS, we investigated an HER-1 inhibitor, gefitinib, in refractory SyS...
  17. ncbi request reprint Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup
    Ian J Lewis
    Paediatric Oncology and Haematology, St James University Hospital, Leeds, UK
    J Natl Cancer Inst 99:112-28. 2007
    ..It was then proposed that survival could be improved by increasing the planned dose intensity of cisplatin and doxorubicin...
  18. ncbi request reprint Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer
    Jacques Bernier
    Department of Radio Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    N Engl J Med 350:1945-52. 2004
    ..We compared concomitant cisplatin and irradiation with radiotherapy alone as adjuvant treatment for stage III or IV head and neck cancer...
  19. ncbi request reprint Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma
    Sophie D Fossa
    Department of Oncology, The Norwegian Radium Hospital, Oslo, Norway
    Cancer 101:533-40. 2004
    ..In 1995, preclinical and clinical data indicated an improvement of these results if IFN was combined with 13-cis retinoic acid (CRA)...
  20. doi request reprint Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii89-93. 2008